WEBSITECHANGES

Website Changes

---

09/18/2024

Share Your Experiences With Glioblastoma Multiforme (GBM)

---

08/26/2024

Boy, 11, denied life-extending drug as his incurable `octopus tumour` is 1 millimetre too small

---

08/26/2024

Metabolic signatures derived from whole-brain MR-spectroscopy identify early tumor progression in high-grade gliomas using machine learning

---

08/15/2024

2025 College Scholarship $ is Available!

---

08/12/2024

A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine

---

08/12/2024

ACTION ALERT for New York residents - Medicaid coverage for Tumor Treating Fields

---

08/12/2024

Vorasidenib Approved by FDA for Grade 2 IDH-Mutant Glioma

---

08/12/2024

Musella Foundation Brain Tumor Treatment Copayment Assistance Program is now closed to new patients

---

08/05/2024

Musella Foundation Brain Tumor Treatment Copayment Assistance program is almost closed

---

08/05/2024

Machine Learning-Directed Conversion of Glioblastoma Cells to Dendritic Cell-like Antigen-Presenting Cells as Cancer Immunotherapy

---

07/22/2024

Duke Phase 2 poliovirus trial for recurrent glioblastoma open for enrollment

---

07/22/2024

Webinar on LTSL-Dox plus Hyperthermia now available

---

07/22/2024

Update from our friends at Roon!

---

07/22/2024

Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated BBB opening: a novel combinatorial immunotherapy regimen for gliomas

---

07/15/2024

Global post-marketing safety surveillance of Tumor Treating Fields (TTFields) therapy in over 25,000 patients with CNS malignancies treated between 2011-2022

---

07/15/2024

Musella Foundation Is Now Accepting Cryptocurrency Donations

---

07/12/2024

Expanded Access Program for gallium maltolate (GaM) Now Open

---

07/08/2024

Musella Foundation Copay Assistance Program is now open!

---

07/01/2024

Application of Delta T1 maps for quantitative and objective assessment of extent of resection and survival prediction in glioblastoma

---

07/01/2024

No benefit from TMZ treatment in GB with truly unmethylated MGMT promotor: Reanalysis of the CE.6 and the pooled Nordic/NOA-08 trials in elderly GB

---

07/01/2024

Exhaustive in vitro evaluation of the 9-drug cocktail CUSP9 for treatment of glioblastoma

---

07/01/2024

Musella Foundation Awards Research Grant

---

06/23/2024

FDA Expands Orphan Drug Designation for SurVaxM, Immunotherapy Developed at Roswell Park

---

06/13/2024

Medicenna Reports Significant Survival Benefit in Patients with Recurrent Glioblastoma Following Treatment with Bizaxofusp When Compared to a Matched External Control Arm at the 2024 ASCO Annual Meeting

---

06/12/2024

Musella Foundation Earns a Four-Star Rating From Charity Navigator

---